Pelmeg União Europeia - norueguês - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastim - nøytropeni - immunostimulants, - for å redusere varigheten av neutropenia og forekomsten av febrile neutropenia på grunn av kjemoterapi.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) União Europeia - norueguês - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Rivastigmine 1 A Pharma União Europeia - norueguês - EMA (European Medicines Agency)

rivastigmine 1 a pharma

1 a pharma gmbh - rivastigmin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatisk behandling av mild til moderat alvorlig alzheimers demens. symptomatisk behandling av mild til moderat alvorlig demens hos pasienter med parkinsons sykdom.

Pioglitazone Teva Pharma União Europeia - norueguês - EMA (European Medicines Agency)

pioglitazone teva pharma

teva pharma b.v. - pioglitazonhydroklorid - diabetes mellitus, type 2 - legemidler som brukes i diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. etter initiering av behandling med pioglitazon, pasienter bør vurderes etter 3 til 6 måneder for å vurdere tilstrekkeligheten av respons på behandling (e. reduksjon i hba1c). hos pasienter som ikke klarer å vise et adekvat svar, pioglitazon bør seponeres. i lys av potensiell risiko med langvarig behandling, prescribers bør bekrefte på følgende rutine anmeldelser dra nytte av pioglitazone er opprettholdt.

Ixiaro União Europeia - norueguês - EMA (European Medicines Agency)

ixiaro

valneva austria gmbh - japanese-encephalitis virus, inaktivert (dempet stamme sa14-14-2 dyrket i vero celler) - encephalitis, japanese; immunization - vaksiner - ixiaro er indisert for aktiv immunisering mot japansk encefalitt hos voksne, ungdom, barn og spedbarn i alderen to måneder og eldre. ixiaro bør vurderes for bruk i personer med risiko for eksponering gjennom reiser eller i løpet av sitt yrke.

Clopidogrel Acino Pharma GmbH União Europeia - norueguês - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.

Laktulose MIP Pharma 650 mg/ ml Noruega - norueguês - Statens legemiddelverk

laktulose mip pharma 650 mg/ ml

mip pharma gmbh - laktulose - mikstur, oppløsning - 650 mg/ ml

Nyxthracis (previously Obiltoxaximab SFL) União Europeia - norueguês - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immune sera og immunglobuliner, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Iomeron 400 mg I/ ml Noruega - norueguês - Statens legemiddelverk

iomeron 400 mg i/ ml

bracco imaging spa - jomeprol - injeksjonsvæske, oppløsning - 400 mg i/ ml

Iomeron 150 mg I/ ml Noruega - norueguês - Statens legemiddelverk

iomeron 150 mg i/ ml

bracco imaging spa - jomeprol - injeksjonsvæske, oppløsning - 150 mg i/ ml